Glucocorticoids are stress hormones. Think cortisol, dexamethasone, that whole family. They bind the glucocorticoid receptor, which then heads into the nucleus and starts flipping genetic switches like a tired office manager with too much authority and not enough supervision [6,7]. In cancer, that gets awkward fast. These hormones can reduce inflammation, which sounds nice, but they can also tone down the very immune responses you might want fighting a tumor.
That tension is already a live issue in lung cancer. A 2024 review on glucocorticoids in lung cancer describes them as a swinging pendulum - sometimes helpful, sometimes immunosuppressive, often both before lunch [2]. A 2025 systematic review and meta-analysis also flagged ongoing concern about steroid exposure around immune checkpoint inhibitor treatment in NSCLC [5]. Translation: steroids are medically useful, but cancer biology loves turning useful things into accomplices.
What this new paper actually did
Hong and colleagues came in with a very "what if we stop guessing and interrogate the genome" energy [1]. Instead of just asking whether glucocorticoid-related genes show up in lung cancer, they used Mendelian randomization, which is basically nature's chaotic version of a randomized trial. If certain inherited variants that influence gene expression also track with cancer risk, that strengthens the case that the gene is not just hanging around in the background eating chips.
They identified glucocorticoid-related genes with potential causal links to NSCLC, then layered in single-cell RNA sequencing and imaging data. That matters because tumors are not just blobs of bad cells. They are weird little neighborhoods full of immune cells, structural cells, blood vessels, and at least one resident troublemaker.
The especially interesting troublemakers here were M2 macrophages. These are the "please keep things calm and tidy" macrophages that tumors often recruit and weaponize. In healthy settings, that calming behavior can help with repair. Inside cancer, it can look more like a security team that accidentally starts escorting the criminals to the vault. The paper found higher glucocorticoid-related gene module scores in M2 macrophages from NSCLC tissue than in nearby normal tissue [1].
Then the authors combined three genes - MRPS7, IQGAP1, and EXOC2 - with M2 macrophage abundance, clinical variables, and radiomics features from scans to build a prognostic model. In their training cohort, the 1-year survival AUC was above 0.9, and performance held up reasonably well in the test cohort across 1 to 5 years [1]. That is the sort of result that makes researchers sit up straighter and clinicians squint respectfully.
Why the macrophage angle is such a big deal
This paper did not appear out of nowhere. Recent work has been piling up around the idea that lung tumors are expert manipulators of macrophages.
A 2024 Molecular Cancer study showed that in lung adenocarcinoma, the proximity of M2 macrophages to other immune cells matters a lot. Helpful immune cells looked less helpful when they were hanging out next to M2 macrophages, which is a bit like discovering your star witness has been seated beside a very persuasive mob lawyer [4]. An eLife review from 2023 also emphasized how central macrophage subtypes are to NSCLC biology and why better models are needed to study them [3].
There is an even stranger twist. A 2023 Genes & Immunity paper reported that human lung carcinomas can actually synthesize immunoregulatory glucocorticoids themselves [8]. Yes, the tumor may not just be responding to the body's stress chemistry. It may be cooking up some of its own. Cancer, once again, proving it is not content with one evil side hustle.
And in 2021, Nature Communications showed glucocorticoid receptor activation could push lung cancer cells into a reversible drug-tolerant dormancy state [9]. So glucocorticoid signaling may influence immune escape, cell state, and treatment response. Very efficient. Very rude.
Why you should care, even if you were just trying to enjoy one beverage in peace
If these findings hold up, they point toward a future where lung cancer prognosis is not based only on what the tumor looks like under a microscope, but on a mashup of genetics, immune ecology, and imaging. That is more realistic because cancer is not one problem. It is a committee meeting from hell.
The practical dream here is twofold. First, better risk prediction. Second, better targets. If glucocorticoid-related pathways are helping shape M2 macrophage behavior, then disrupting that crosstalk might make tumors less able to hide, stall, or charm the immune system into doing absolutely nothing.
There are still caveats. Mendelian randomization is powerful, but it is not magic. M2 macrophages are a useful label, though real macrophages are more complicated than the M1-good, M2-bad cartoon. And a strong prognostic model is not the same thing as a clinic-ready test. Plenty of models look brilliant in development and then faceplant in the real world like a superhero tripping over a garden hose.
Still, this study puts real weight behind an idea that has been buzzing around the field: glucocorticoid signaling in lung cancer is not just background noise. It may be part of the script.
References
-
Hong T, Su L, Xue W, et al. Causal inference of glucocorticoid signaling in non-small cell lung cancer: integrating Mendelian randomization, single-cell transcriptomics, and imaging data. NPJ Precision Oncology. 2026. DOI: https://doi.org/10.1038/s41698-026-01421-1
-
Xu W, Ye J, Cao Z, et al. Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy. Heliyon. 2024;10(12):e32357. DOI: https://doi.org/10.1016/j.heliyon.2024.e32357. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11252876/
-
Liegeois M, Vazquez-Armendariz AI, Marchan R, et al. The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures. eLife. 2023;12:e82998. DOI: https://doi.org/10.7554/eLife.82998. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9943070/
-
Li JR, Shaw V, Lin Y, et al. The prognostic effect of infiltrating immune cells is shaped by proximal M2 macrophages in lung adenocarcinoma. Molecular Cancer. 2024;23:185. DOI: https://doi.org/10.1186/s12943-024-02080-1
-
Impact of glucocorticoid administration on therapeutic outcomes of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. 2025. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC12580123/
-
Glucocorticoid receptor. Wikipedia. https://en.wikipedia.org/wiki/Glucocorticoid_receptor
-
Macrophage polarization. Wikipedia. https://en.wikipedia.org/wiki/Macrophage_polarization
-
Merk VM, Grob L, Fleischmann A, Brunner T. Human lung carcinomas synthesize immunoregulatory glucocorticoids. Genes & Immunity. 2023;24(1):52-56. DOI: https://doi.org/10.1038/s41435-023-00194-y. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9935384/
-
Prekovic S, Schuurman K, Mayayo-Peralta I, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications. 2021;12:4360. DOI: https://doi.org/10.1038/s41467-021-24537-3
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.